Objectives: The aim of this prospective study was to assess the influence of different normalisation procedures on relative changes in standardised uptake values (SUV) of FDG-PET for the assessment of chemotherapy response in patients with colorectal carcinoma (CRC) and non-small cell lung carcinoma (NSCLC). Methods: In 97 patients with CRC 5 (n=48) and NSCLC (n=49) FDG-PET was performed before and during the course of chemotherapy. Relative changes in SUV (ΔSUV) were determined after correction for injected dose and bodyweight, lean body mass, body surface area or a combination of bodyweight and plasma glucose. The predictive value for overall (OS) and progression free survival (PFS) with respect to the different normalised ΔSUVs was assessed. Results: In 10 both CRC and NSCLC no differences were seen in the degree of change between the four SUV-normalisations during chemotherapy. Cox regression analysis for OS showed significant hazard ratios of 1.14-1.16 per ten percent SUV-change in CRC and 1.10-1.13 in NSCLC and for PFS hazard ratios of 1.15 per ten percent ΔSUV-change in CRC and 1.10- 
Introduction
Functional imaging by 18 F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has an established role in the standard care of patients with both colorectal carcinoma (CRC) and non-small cell lung carcinoma (NSCLC). Interest in the application of FDG-PET for prediction and evaluation of tumour response to therapy is growing. When using morphological imaging techniques such as computed tomography (CT) or magnetic 30 resonance imaging (MRI) it may be difficult to reliably distinguish between necrosis, scar tissue and recurrent or residual tumour in CRC [1] [2] [3] and NSCLC [4] . Furthermore, metabolic alterations in tumour cells, indicative of tumour response to therapy, may arise earlier than changes in size [5] . Moreover, some new antitumour therapies are cytostatic rather than cytoreductive. Therefore success of treatment cannot reliably be measured on 35 morphologic imaging modalities alone. Early detection of tumour progression during chemotherapy can prevent unbeneficial and potentially harmful treatment and provides the opportunity to modify treatment at an early treatment stage.
In CRC [6] as well as NSCLC [7] [8] [9] a significant prognostic value for overall survival (OS) and progression-free survival (PFS) by (semi)quantitative measures of PET data analysis has been shown. Also, the response to chemotherapy, evaluated as relative change in FDG-PET-assessed tumour metabolism in CRC [10, 11] and NSCLC [9, 12] , proved to be significantly associated with OS and PFS. In these studies it was suggested that less demanding semi-quantitative parameters such as the standardised uptake value (SUV) might perform as well as complex dynamic imaging protocols necessary for 45
Patlak analysis [11, 13] which would facilitate broad introduction in clinical practice by improving patient compliance. Another advantage of the SUV is that it can be calculated from static, whole-body FDG-PET studies, which depict all metastases. In quantitative dynamic scans only one axial field of view (15-20cm) can be studied which could exclude metastases which respond differently to therapy [11] . 50
The present study aims at further standardisation, validation and simplification of the methods necessary for metabolic response assessment. For this purpose four distinct normalisation methods for relative changes in SUV (ΔSUV) were evaluated in two patient populations (CRC and NSCLC). SUVs were determined from scans performed on one bed position only, since this study was part of a larger project, which included dynamic 55 acquisition. This single axial field of view was chosen to include as many lesions as possible, based on the baseline whole-body staging FDG-PET, acquired at an earlier time point.
. Overall and progression free survival were used as outcome measures. For absolute SUV measurement the different normalisation procedures are already extensively 60 compared in former studies [14] , of which some seem superior to others [13, 15] when compared to full parameter pharmacokinetics by nonlinear regression. These studies, however, address the prognostic value of SUV by its absolute value. In contrast, in the present study, the relative value will be examined, which is of importance in therapy response monitoring.
Patients and methods

Patient eligibility criteria
Patients eligible for the FDG-PET chemotherapy response monitoring studies on CRC [11] and NSCLC [12] were included in the present study. In all patients, treatment decisions 70 were based on current guidelines and made by a multidisciplinary team including medical oncologists, oncological and cardio-thoracic surgeons, pulmonologists, radiation oncologists, pathologists, radiologists and nuclear medicine physicians. All clinicians were blinded to the results of the FDG-PET scans. The study was approved by the Institutional Review Board of the Radboud University Nijmegen Medical Centre and written informed 75 consent was obtained from each patient.
FDG-PET
FDG-PET was performed at baseline and after two months of treatment (CRC) or after the second or third cycle of chemotherapy (NSCLC), depending on the chemotherapy regimen. 80
Patients were fasted for at least 6h before imaging. Intake of sugar-free liquids was permitted. A dose of ~200MBq FDG (Covidien, Petten, the Netherlands) was injected intravenously. All scans were acquired between 40 and 50 minutes post injection on an ECAT-EXACT47 FDG-PET scanner (Siemens/CTI, TN, USA) in septa-extended (2-dimensional) mode. The position of the patient in the scanner's field of view (162mm in 47 85 planes) was based on whole-body FDG-PET and CT scans performed for routine clinical work-up, including as many measurable tumour lesions as possible. Only one field of view was scanned, since this study was part of a larger project, which included dynamic scanning [11, 12] . A 20-min transmission scan was performed, using the internal 68 Ge/ 68 Ga sources, to correct for photon attenuation, the duration of which was chosen to provide a higher 90 signal-to-noise ratio. The emission and transmission sinograms were corrected for randoms and decay. Scatter correction based on measured scatter fractions as implemented in the ECAT 7.2.1. software for 2D reconstructions was used. Attenuation-corrected images were reconstructed in 128x128x47 matrices using filtered backprojection with a Gaussian filter of 4 mm full width at half maximum (FWHM). This resulted in voxels of 3.432mm x 95 3.432mm x 3.375mm and a spatial resolution of 6mm FWHM in the reconstructed images.
FDG-PET scans were evaluated semi-quantitatively by standardised uptake value (SUV) analysis. Tumour regions of interest (ROI) were obtained semi-automatically using a threshold of 50% of the maximum pixel value within the lesion. Four different SUVs, based on injected dose and bodyweight (SUV BW ), lean body mass (SUV LBM ), body surface 100 area (SUV BSA ) and a combination of bodyweight and plasma glucose (SUV BW+G ) were calculated (table 1) [14] . The injected dose was calculated by subtraction of the residual 18 F-activity of the infusion system from the 18 F-activity delivered by the laboratory, corrected for decay to time of injection: 
Clinical Follow-Up
During and after treatment, patients were followed-up with clinical-and radiological examination and laboratory tests at regular intervals. Morphologic tumour response was routinely evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) 120 [16] without knowledge of the results of the FDG-PET studies. These criteria define progression as a 20% increase in the sum of longest diameters of target lesions or the appearance of new lesion [16] . When disease progression was suspected or proven, patients were always restaged by the previously mentioned multidisciplinary team. The date of local or distant progression was defined as the earliest date at which disease progression was 125 confirmed, either clinically or by imaging or biopsy.
In patients who were progression free at the closeout date (April 2008) or who had died from any non-tumour related cause, the time to progression was censored at that date.
Overall survival was measured from the date of the baseline FDG-PET scan to the date of death. In patients who were alive at the closeout date, survival was censored at that date. 130
Statistical Analysis
Normality of the data was assessed by the Shapiro-Wilk statistic. 
Results
160
Patient characteristics
One hundred and twenty consecutive eligible patients were included in this prospective study (61 advanced CRC, 59 NSCLC). After the baseline FDG-PET, 23 patients (13 CRC, 10 NSCLC) were excluded for several reasons: due to technical issues (n=7), refusal to undergo a second FDG-PET (n=3), death before the second FDG-PET (n=3) and early 165 discontinuation of chemotherapy due to a significant decline in performance status (n=10). 
Semi-quantitative changes in FDG uptake 180
Median interval between baseline and follow-up FDG-PET was 8.9 weeks (IQR 7.0-9.6) in the CRC-group and 7.0 weeks (IQR 5.9-8.6) in the NSCLC-group. Box-and-whisker plots of ΔSUVs are displayed in figure 1. In both CRC and NSCLC the decline in median of all four SUVs between first and second FDG-PET was statistically significant (p<0.001). No significant differences between the four compared ΔSUVs could be found in CRC 185 (p=0.143) and NSCLC (p=0.059).
In CRC differences in metabolic response between ΔSUV LBM , ΔSUV BSA and ΔSUV BW+G compared to ΔSUV BW was more than the reproducibility limit in 1, 0 and 5 of 48 cases respectively. In NSCLC this was 0, 0 and 5 of 49 cases respectively. To assess for predictive ability of the four normalisation methods of metabolic 195 treatment response as to OS and PFS, patients were dichotomised to the median ΔSUV.
Results are displayed in table 5.
In CRC using a cut-off for ΔSUV of -33% for BW, LBM and BSA and -22% for BW+G separated patients who had 90% 1-year OS from those with lower OS rates. In NSCLC these cut-offs were -56% for BW, -57% for LBM and BSA and -53% for BW+G. 200
The group defined as metabolic responders consisted of 24-31% of the patients. In contrast to CRC, in NSCLC these numbers were very different from the medians (~-37%). This prognosis-driven dichotomisation for NSCLC for OS resulted in median ratios of 0.28 (HR 2.8, log rank p=0.001) for ΔSUV BW and ΔSUV BW+G and 0.22 (HR 3.1, log rank p<0.001) for ΔSUV LBM and for ΔSUV BSA . 205
Discussion
In this study, we showed for the first time that the method for SUV-normalisation does not influence the predictive value of FDG-PET in CRC and NSCLC in chemotherapy response monitoring. The predictive value of FDG-PET for CRC [6] and NSCLC [19] [20] [21] [22] [23] [24] [25] has been 210 studied extensively and is an established predictor for survival. Chemotherapy response monitoring in CRC was performed by different groups, all using absolute [10, 26, 27] or relative [11] SUV BW differences as a measure for change in metabolic activity. In NSCLC, relative changes in SUV as result of therapy have been observed in numerous studies. Some used BW normalised SUV [12, [28] [29] [30] , others used normalisation by BSA and serum 215 glucose [9] . However, for metabolic response assessment none so far investigated which of the different normalisations is optimal as compared to overall and progression free survival.
In both CRC and NSCLC, all four normalised SUVs showed a significant decrease between baseline and follow-up FDG-PET. Although it was shown that bodyweight (in CRC) and serum glucose (in NSCLC), the major factors for normalisation of SUV, were 220 significantly different between both baseline and follow-up scan, we did not find mutual differences between the four ΔSUV-normalisations. This suggests that there is no preference for either any of the four normalisations in SUV when therapy response is measured by relative changes in SUVs between baseline and follow-up FDG-PET.
Krak et al. [17] describe that standard deviation between two consecutive scans 225 (made on 2 consecutive days) was 11% using the same definition of ROI as in this study.
Therefore SUVs on 2 consecutive days may vary ~±20% due to reproducibility limits of the test. Using this as a cut-off for a significant different ΔSUV between the 2 normalisations we found that especially in ΔSUV BW+G more often a change in metabolism was found Choosing a cut-off value of metabolic response for 90% 1-year OS, led to a median survival ratio of 0.22-0.28 for metabolic non-responders versus responders. In CRC 235 the effect of abovementioned cut-off was similar to the median SUV change (and thus selects ~50% best responders).
We observed higher hazard ratios for NSCLC than CRC. This suggests that similar reduction in SUV in CRC has less effect on patient overall survival than in NSCLC. This may be caused by biological differences and differences in chemosensitivity of both types 240 of cancer. However, changes in glucose metabolic rate, are not only dependent on biological behaviour of the tumour to the given treatment, but are also dependent on the treatment protocol and the timing of follow-up scanning. Both these biological differences and variation in treatment and follow-up protocol hinder determination of optimal cut-offs.
Therefore standardisation of response measurement protocols are necessary and cut-offs 245 should be dependent of tumour-type, antitumour treatment and timing of evaluation.
Earlier publications [11, 12] showed that SUV is a sufficiently robust measure for treatment response monitoring and can reliably replace more complex, invasive and timeconsuming measures such as Patlak analysis which determines glucose metabolic rate (MR glc ). Apart from being a less time-consuming method, SUV can be calculated from a 250 whole-body FDG-PET study including all metastatic lesions. Furthermore, no input function is required for SUV-determination. The advantage of relative SUV-determination compared to absolute SUVs, however, is that it is easier to combine data from different studies because they are less sensitive to introduction of errors due to noise, image resolution and ROI-definition compared to absolute SUVs [17, [31] [32] [33] . If the patient is 255 scanned in the same hospital on the same scanner, some scanner related factors and patient related factors can be ignored [33] .
Different normalisation methods for absolute SUV values have been addressed by others [34] [35] [36] [37] [38] , reporting varying results. Some have shown that SUV corrected for BSA proved to be more accurate, in adult [34] and paediatric [38] patients, compared to the gold 260 standard MR glc . It was suggested that normalisation is necessary because of variability in SUV due to body composition and habitus as well as plasma glucose [32, 39] . Menda et al. [36] observed no advantage of any SUV correction for accuracy of diagnosis of pulmonary malignancy. In contrast with our study, these studies did not address therapy response, and therefore did not take into consideration the measurement of relative changes in SUV. 265 Krak et al. [35] compared different normalisations for relative SUV change in 20 women with locally advanced or metastasised breast cancer with the golden standard of non-linear regression after 1, 2 or 6 courses of chemotherapy. They concluded that of the investigated normalisation methods, relative change of SUV corrected for both LBM and glucose showed highest correlation with relative change in glucose metabolic rate as 270 calculated by non-linear regression. This study did not correlate SUV corrections with clinical outcome parameters such as patient survival.
Stahl et al. [37] compared histological response in 43 patients with locally advanced gastric carcinomas with the same four normalisations for relative SUV change as in our study, between baseline and follow-up FDG-PET (after 2 weeks, during first cycle of 275 platinum-based chemotherapy). They, too, concluded that no normalisation method of ΔSUVs has an advantage for response prediction and that the theoretical benefits of the measures to reduce the dependency of the SUV on BW or plasma glucose do not translate into a detectable clinical benefit.
Our study showed no preference of any SUV-normalisation in therapy response 280 monitoring in CRC and NSCLC. This could be caused by the fact that SUVs used in therapy response monitoring are compared in individual patients and not between different patients. It can be easily derived that an increase in bodyweight alone of 10%, increases ΔSUV BW and ΔSUV BW+G by 10%, ΔSUV BSA by 4.1% (=[1. 10] 0.425 -1) and has no effect on ΔSUV LBM . An increase of plasma glucose alone of 10% increases ΔSUV BW+G by 10%. The 285 effect of chemotherapy and disease on body composition seems to be relatively small.
Therefore it is possible to select the SUV, which is simplest, without introduction of extra parameters like bodyweight, length or serum glucose. All these parameters necessitate calibration and may for that reason potentially introduce extra uncertainties. Moreover, simplifying FDG-PET methodology in therapy response monitoring could facilitate its 290 introduction in routine clinical practice.
The variety of applied analytical methods is vast, which hampers multicentre research. Clear methods for standardisation of acquisition, reconstruction, ROIdetermination and SUV-normalisation need to be determined [33] . In fact, methodology of metabolic response evaluation needs to be standardised in evidence based multidisciplinary 295 international guidelines. This has been attempted previously by the European Organisation for Research and Treatment of Cancer (EORTC) [40] and the National Cancer Institute (NCI) [15] . However, they provide consensus-based recommendations, rather than advicebased on scientific proof. Evidence-based guidelines would be of utmost importance for the interpretation and comparison of multicentre trials. 300
Conclusion
In chemotherapy response evaluation in both CRC and patients with NSCLC, relative SUV changes in FDG-PET have high predictive value for patient survival. Using relative changes in tumour FDG-uptake for a patient, no normalisation for body habitus in SUV-305 calculation seems superior, since all perform equally well for prediction of survival in both types of cancer. Therefore theoretical advantages of one normalisation method over another, do not translate into clinical relevant changes. This finding in combination with the fact that relative (rather than absolute) changes are less dependent of quantitative PET acquisition protocols [17, 31] 
